Trial Profile
Ilaris (canakinumab) efficacy and safety in CAPS patients without confirmed mutation on exon 3 of gene CIAS1 and young (<2yrs) CAPS patients with severe neurological (CINCA) phenotype.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 09 Mar 2023
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Cryopyrin-associated periodic syndromes
- Focus Therapeutic Use
- 09 Mar 2023 Status changed from recruiting to discontinued.
- 13 Oct 2014 New trial record